June 21, 2022

Venatorx is excited to be a part of this significant collaborative initiative that will enhance and centralize access to high-quality AMR surveillance data across multiple datasets around the globe. Vivli’s AMR Register is vital to support educational and scientific communications on the AMR burden and emerging resistance, as well as global public health at large.

April 04, 2022

Venatorx Pharmaceuticals announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.

March 10, 2022

Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.

December 02, 2021

With over 20 years’ experience in infectious disease, oncology, rare and orphan diseases and academia, Dr. McConnell will be responsible for leading the medical affairs function at Venatorx and will oversee the planning and execution of medical strategy, field medical engagement and scientific communications.

November 01, 2021

Venatorx Pharmaceuticals entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”) in Gram-negative bacteria focused on agents active against carbapenem-resistant Enterobacterales (CRE).

September 27, 2021

Venatorx Pharmaceuticals, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.

August 17, 2021

Venatorx Pharmaceuticals announced a comprehensive update about cefepime-taniborbactam, the Company’s intravenous beta-lactam / beta-lactamase inhibitor combination antibiotic that is being developed for the treatment of cUTIs and HABP/VABP.

July 28, 2021

VNRX-7145, in combination with ceftibuten, is designed for the treatment of patients with infections caused by multi-drug resistant (MDR) gram-negative pathogens that are resistant to current standard-of-care oral and intravenous antibiotics, including fluoroquinolones, cephalosporins and carbapenems.

Archive: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010